242 related articles for article (PubMed ID: 15836919)
1. Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.
Chen J; Lee CT; Errico S; Deng X; Cadet JL; Freed WJ
Brain Res Mol Brain Res; 2005 Apr; 134(2):215-25. PubMed ID: 15836919
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity.
Kim SH; Won SJ; Mao XO; Jin K; Greenberg DA
Mol Pharmacol; 2006 Mar; 69(3):691-6. PubMed ID: 16299067
[TBL] [Abstract][Full Text] [Related]
3. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
Liu Q; Bhat M; Bowen WD; Cheng J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
[TBL] [Abstract][Full Text] [Related]
4. Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
Carroll CB; Zeissler ML; Hanemann CO; Zajicek JP
Neuropathol Appl Neurobiol; 2012 Oct; 38(6):535-47. PubMed ID: 22236282
[TBL] [Abstract][Full Text] [Related]
5. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
Araya KA; David Pessoa Mahana C; González LG
Eur J Pharmacol; 2007 Oct; 572(1):32-9. PubMed ID: 17644088
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores.
Zhuang SY; Bridges D; Grigorenko E; McCloud S; Boon A; Hampson RE; Deadwyler SA
Neuropharmacology; 2005 Jun; 48(8):1086-96. PubMed ID: 15910885
[TBL] [Abstract][Full Text] [Related]
8. Delta 9-tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed.
Wilkinson JD; Kendall DA; Ralevic V
Br J Pharmacol; 2007 Nov; 152(5):709-16. PubMed ID: 17828286
[TBL] [Abstract][Full Text] [Related]
9. Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.
De Vry J; Jentzsch KR
Behav Pharmacol; 2004 Feb; 15(1):13-20. PubMed ID: 15075622
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite.
El-Remessy AB; Khalil IE; Matragoon S; Abou-Mohamed G; Tsai NJ; Roon P; Caldwell RB; Caldwell RW; Green K; Liou GI
Am J Pathol; 2003 Nov; 163(5):1997-2008. PubMed ID: 14578199
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
Wiley JL; Lowe JA; Balster RL; Martin BR
J Pharmacol Exp Ther; 1995 Oct; 275(1):1-6. PubMed ID: 7562536
[TBL] [Abstract][Full Text] [Related]
12. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.
Järbe TU; LeMay BJ; Halikhedkar A; Wood J; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2014 Feb; 231(3):489-500. PubMed ID: 24005529
[TBL] [Abstract][Full Text] [Related]
13. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity.
Gilbert GL; Kim HJ; Waataja JJ; Thayer SA
Brain Res; 2007 Jan; 1128(1):61-9. PubMed ID: 17140550
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression.
Pozzoli G; Tringali G; Vairano M; D'Amico M; Navarra P; Martire M
J Neurosci Res; 2006 May; 83(6):1058-65. PubMed ID: 16609959
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
17. Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats.
del Carmen García M; Adler-Graschinsky E; Celuch SM
Naunyn Schmiedebergs Arch Pharmacol; 2003 Oct; 368(4):270-6. PubMed ID: 14504685
[TBL] [Abstract][Full Text] [Related]
18. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
Darmani NA; Chebolu S; Zhong W; Trinh C; McClanahan B; Brar RS
Eur J Pharmacol; 2014 Jan; 722():147-55. PubMed ID: 24157976
[TBL] [Abstract][Full Text] [Related]
19. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action.
Köfalvi A; Vizi ES; Ledent C; Sperlágh B
Eur J Neurosci; 2003 Oct; 18(7):1973-8. PubMed ID: 14622229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
